SpyGlass Pharma Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hi, good morning and welcome to the Jefferies London Healthcare Conference. My name is Dennis Ding, biotech analyst here at Jefferies, and I have the wonderful pleasure of introducing the SpyGlass team here. Welcome. For people who aren't necessarily aware of SpyGlass, because you guys were a relatively new IPO, maybe just remind us of what you guys are trying to do and some of the progress that you guys have made this year.
Sure. Good morning, Dennis. Thanks for the time today. SpyGlass has been in existence for seven years. Company was founded in 2019. The simple premise is to take care of patients that are undergoing cataract surgery that also have concomitant glaucoma. The novel BIM-IOL, or bimatoprost intraocular lens system, is currently being studied in phase III registrational trials to not only restore vision from cataracts, but also to lower intraocular pressure for the 20% of patients undergoing cataract surgery that also have glaucoma. This team has continued to execute really well. We released our one-year phase II data last year, four-year readout on our first-in-human for BIM-IOL. We just initiated our secondary platform, the Bimatoprost-Drug Ring System, in a first-in-human trial as well. We guided to hit all those.
We have continued to perform on time, and we're excited to advance the team forward. As you know, we took the company public back in February. So 2026 has been an excellent year for us to continue our program and execute on our aspirations.
Perfect. Before we kind of get into a little bit of your data, maybe just remind us the TAM and the unmet need out there.
Sure. There is 1 million incident procedures done in the U.S. every year. These are patients with glaucoma undergoing cataract procedures. It is about 20% of the overall, 5 million total cataracts. It is a really large market. We are only living longer and the population is growing, so this is certainly an area of big market today of 1 million procedures, but growing annually at about 3%. With the current incident procedures of 1 million times current list prices of products in market today for three years of drug delivery, it is a $13 billion TAM.
Perfect. Maybe just remind us a little bit about BIM-IOL, and some of the data that you guys have shown.
Sure. BIM-IOL, or intraocular lens system, we are showing out to one year in our phase II data and out to four years in our first-in-human data. Essentially, we are showing that we are able to correct vision, a whole line of vision better than the standard for lens approvals, as well as deliver durable intraocular pressure lowering. Out to four years in our first-in-human data, 37% mean IOP reduction, which is on par or better than a standard topical prostaglandin analog. We are also showing, at four years, 86% of patients remain off of all topical therapy, which is impressive. At one year, in our phase II randomized controlled clinical trial, we are showing 98% of patients off of all topical intraocular pressure lowering meds. Known drug, bimatoprost, it has been used commercially globally for two decades.
That drug works very well in a topical form, and obviously we are starting it in our sustained drug delivery system. But showing continued efficacy, not only for restoring vision, but also to continue to lower intraocular pressure for years.
Sure. When you talk with doctors, what do they perceive as clinically meaningful, especially for a long-acting implant?
Topically, these drugs are expected to lower pressure 20%-30%. Anywhere in that neighborhood of 20%-30% is what doctors would expect. When we're reaching well beyond 30% at year one in a randomized controlled trial, or out to 37% four years in our first-in-human, we're exceeding their expectation just of the topical drop therapy itself. Now, I'll caveat that we are a combined procedure. It is cataract surgery. We know cataract removal of your natural lens does lower intraocular pressure roughly 10%-15%. What we're seeing is a sustained, durable 30-plus percent reduction in pressure in between our two clinical trials to date. We haven't seen is that taper off, if you will, in terms of pressure reduction. At least out to four years, we can stand behind confidently that our system continues to lower pressure for years.
Sure. You guys are in phase III, and we'll get some of that data perhaps late 2027.
Yes, we are in phase III pivotal trials. It's about 800 patients in total between both trials. We are right on track with our enrollment. Team is executing very well. I would say late Q4 2027 is our target for releasing top-line data. We're on track to finish our trial next year. That's what we've guided to. We'll submit the New Drug Application in 2028, and with approval, we'll launch in 2029.
What should we expect in terms of efficacy in the phase III, in terms of the IOP reduction?
The primary endpoint is non-inferiority to timolol. We know timolol is a beta blocker, works very well to lower pressure. Prostaglandins also work very well. These are non-inferiority trials to timolol, essentially within 1.5 millimeters of timolol at all time points. We can expect a similar type of durable efficacy. You are going to see this is essentially a three-month registration trial. The target product profile is meant for years, so you will not necessarily see the payout of a durable system for years. We like the opportunity to register this system with standard FDA benchmarks of three months of efficacy. I think you will see efficacy at IOP lowering, and you will also see quality vision for patients. FDA wants to see 20/40 vision or better for your lens approval.
In all of our clinical trials to date, every patient has been a full line of vision better than that at 20/30 or better.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
